Opinion|Videos|July 8, 2024
AE Management With IO-TKI and IO-IO in RCC
Author(s)Martin H. Voss, MD
Martin H. Voss, MD, outlines adverse events encountered with different IO-TKI and IO-IO combination regimens in RCC and discusses the importance of open communication with patients.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- What are the most significant adverse events seen with different IO-TKI and IO-IO combination regimens used in renal cell carcinoma (RCC)?
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Breakthrough Status to Multi-Cancer Early Detection Blood Test
2
Epigenomic ctDNA Assay Predicts Recurrence in Resected Melanoma
3
Alpha-Emitting RYZ101 Meets Phase 3 PFS End Point in Advanced GEP-NETs
4
FDA Clears Phase 2 Trial of B7-H3 CAR T MT027 for Brain Metastases
5